---
document_datetime: 2025-12-29 11:28:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zurzuvae.html
document_name: zurzuvae.html
version: success
processing_time: 0.1045189
conversion_datetime: 2025-12-31 02:00:14.94671
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zurzuvae

[RSS](/en/individual-human-medicine.xml/263613)

##### Authorised

This medicine is authorised for use in the European Union

zuranolone Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zurzuvae](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zurzuvae is an antidepressant medicine used to treat postpartum depression in adults.

Postpartum depression is depression that affects individuals after childbirth, with symptoms such as persistent feelings of sadness, anxiety, and fatigue.

Zurzuvae contains the active substance zuranolone.

Expand section

Collapse section

## How is Zurzuvae used?

Zurzuvae is available as capsules to be taken by mouth once a day in the evening. The medicine is taken for 14 days and can be used alone or in addition to other antidepressant treatment that the patient may already be taking.

The medicine can only be obtained with a prescription.

For more information about using Zurzuvae, see the package leaflet or contact your doctor or pharmacist.

## How does Zurzuvae work?

The active substance in Zurzuvae, zuranolone, increases the activity of the neurotransmitter GABA, which is involved in regulating mood. Neurotransmitters such as GABA are chemicals that allow nerve cells to communicate with each other. In the brain, GABA reduces the ability of nerve cells to communicate, which has a calming effect. By increasing GABA's effects, zuranolone helps to improve mood.

## What benefits of Zurzuvae have been shown in studies?

A main study involving 200 women with severe postpartum depression found that Zurzuvae is more effective than placebo (a dummy treatment) at improving symptoms of depression, as measured using the Hamilton depression rating scale (also called HAMD-17). A reduction in HAMD-17 score indicates an improvement in symptoms.

In the study, women took Zurzuvae or placebo for 14 days. By the 15th day, women treated with Zurzuvae had a reduction of around 16 points in the HAMD-17 score, while those taking placebo had a reduction of around 12 points.

Supportive data showed that by the third day of treatment, the score had dropped by around 10 points in women who were taking Zurzuvae, compared with around 6 points in those taking placebo. Furthermore, 45 days after starting treatment, the HAMD-17 score was around 18 points lower for women who had taken Zurzuvae and around 14 points lower for those on placebo.

## What are the risks associated with Zurzuvae?

For the full list of side effects and restrictions with Zurzuvae, see the package leaflet.

The most common side effects with Zurzuvae (which may affect more than 1 in 10 people) include sleepiness, dizziness and drowsiness.

Zurzuvae must not be taken during pregnancy.

## Why is Zurzuvae authorised in the EU?

At the time of authorisation, there was an unmet need for treatment of postpartum depression that quickly takes effect. Zurzuvae was shown to be effective at bringing about a rapid improvement in symptoms of the condition, and the improvement was maintained throughout the study. The side effects were generally mild and tended to become less frequent after several days of treatment. The European Medicines Agency therefore decided that Zurzuvae's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zurzuvae?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zurzuvae have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zurzuvae are continuously monitored. Suspected side effects reported with Zurzuvae are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zurzuvae

Zurzuvae received a marketing authorisation valid throughout the EU on 17 September 2025.

Zurzuvae : EPAR - Medicine overview

Reference Number: EMA/259050/2025

English (EN) (118.14 KB - PDF)

**First published:** 29/09/2025

[View](/en/documents/overview/zurzuvae-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-132)

български (BG) (140.84 KB - PDF)

**First published:**

29/09/2025

[View](/bg/documents/overview/zurzuvae-epar-medicine-overview_bg.pdf)

čeština (CS) (139.96 KB - PDF)

**First published:**

29/09/2025

[View](/cs/documents/overview/zurzuvae-epar-medicine-overview_cs.pdf)

dansk (DA) (117.49 KB - PDF)

**First published:**

29/09/2025

[View](/da/documents/overview/zurzuvae-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.67 KB - PDF)

**First published:**

29/09/2025

[View](/de/documents/overview/zurzuvae-epar-medicine-overview_de.pdf)

eesti keel (ET) (116.84 KB - PDF)

**First published:**

29/09/2025

[View](/et/documents/overview/zurzuvae-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.58 KB - PDF)

**First published:**

29/09/2025

[View](/el/documents/overview/zurzuvae-epar-medicine-overview_el.pdf)

français (FR) (119.77 KB - PDF)

**First published:**

29/09/2025

[View](/fr/documents/overview/zurzuvae-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.3 KB - PDF)

**First published:**

29/09/2025

[View](/hr/documents/overview/zurzuvae-epar-medicine-overview_hr.pdf)

italiano (IT) (117.96 KB - PDF)

**First published:**

29/09/2025

[View](/it/documents/overview/zurzuvae-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.45 KB - PDF)

**First published:**

29/09/2025

[View](/lv/documents/overview/zurzuvae-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.04 KB - PDF)

**First published:**

29/09/2025

[View](/lt/documents/overview/zurzuvae-epar-medicine-overview_lt.pdf)

magyar (HU) (138.11 KB - PDF)

**First published:**

29/09/2025

[View](/hu/documents/overview/zurzuvae-epar-medicine-overview_hu.pdf)

Malti (MT) (141.33 KB - PDF)

**First published:**

29/09/2025

[View](/mt/documents/overview/zurzuvae-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.83 KB - PDF)

**First published:**

29/09/2025

[View](/nl/documents/overview/zurzuvae-epar-medicine-overview_nl.pdf)

polski (PL) (143.93 KB - PDF)

**First published:**

29/09/2025

[View](/pl/documents/overview/zurzuvae-epar-medicine-overview_pl.pdf)

português (PT) (118.36 KB - PDF)

**First published:**

29/09/2025

[View](/pt/documents/overview/zurzuvae-epar-medicine-overview_pt.pdf)

română (RO) (134.73 KB - PDF)

**First published:**

29/09/2025

[View](/ro/documents/overview/zurzuvae-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.33 KB - PDF)

**First published:**

29/09/2025

[View](/sk/documents/overview/zurzuvae-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138 KB - PDF)

**First published:**

29/09/2025

[View](/sl/documents/overview/zurzuvae-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.69 KB - PDF)

**First published:**

29/09/2025

[View](/fi/documents/overview/zurzuvae-epar-medicine-overview_fi.pdf)

svenska (SV) (116.29 KB - PDF)

**First published:**

29/09/2025

[View](/sv/documents/overview/zurzuvae-epar-medicine-overview_sv.pdf)

Zurzuvae : EPAR - Risk management plan

English (EN) (322.34 KB - PDF)

**First published:** 29/09/2025

[View](/en/documents/rmp/zurzuvae-epar-risk-management-plan_en.pdf)

## Product information

Zurzuvae : EPAR - Product information

English (EN) (394.7 KB - PDF)

**First published:** 29/09/2025

**Last updated:** 31/10/2025

[View](/en/documents/product-information/zurzuvae-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-454)

български (BG) (468.08 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/bg/documents/product-information/zurzuvae-epar-product-information_bg.pdf)

español (ES) (407.78 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/es/documents/product-information/zurzuvae-epar-product-information_es.pdf)

čeština (CS) (450.71 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/cs/documents/product-information/zurzuvae-epar-product-information_cs.pdf)

dansk (DA) (412.42 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/da/documents/product-information/zurzuvae-epar-product-information_da.pdf)

Deutsch (DE) (428.63 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/de/documents/product-information/zurzuvae-epar-product-information_de.pdf)

eesti keel (ET) (407.45 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/et/documents/product-information/zurzuvae-epar-product-information_et.pdf)

ελληνικά (EL) (470.36 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/el/documents/product-information/zurzuvae-epar-product-information_el.pdf)

français (FR) (497.74 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/fr/documents/product-information/zurzuvae-epar-product-information_fr.pdf)

hrvatski (HR) (431.98 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/hr/documents/product-information/zurzuvae-epar-product-information_hr.pdf)

íslenska (IS) (405.86 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/is/documents/product-information/zurzuvae-epar-product-information_is.pdf)

italiano (IT) (436.87 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/it/documents/product-information/zurzuvae-epar-product-information_it.pdf)

latviešu valoda (LV) (457.22 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/lv/documents/product-information/zurzuvae-epar-product-information_lv.pdf)

lietuvių kalba (LT) (439.09 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/lt/documents/product-information/zurzuvae-epar-product-information_lt.pdf)

magyar (HU) (417.52 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/hu/documents/product-information/zurzuvae-epar-product-information_hu.pdf)

Malti (MT) (481.71 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/mt/documents/product-information/zurzuvae-epar-product-information_mt.pdf)

Nederlands (NL) (419.85 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/nl/documents/product-information/zurzuvae-epar-product-information_nl.pdf)

norsk (NO) (406.85 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/no/documents/product-information/zurzuvae-epar-product-information_no.pdf)

polski (PL) (482.33 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/pl/documents/product-information/zurzuvae-epar-product-information_pl.pdf)

português (PT) (437.11 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/pt/documents/product-information/zurzuvae-epar-product-information_pt.pdf)

română (RO) (427.19 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/ro/documents/product-information/zurzuvae-epar-product-information_ro.pdf)

slovenčina (SK) (451.27 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/sk/documents/product-information/zurzuvae-epar-product-information_sk.pdf)

slovenščina (SL) (420.9 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/sl/documents/product-information/zurzuvae-epar-product-information_sl.pdf)

Suomi (FI) (408.02 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/fi/documents/product-information/zurzuvae-epar-product-information_fi.pdf)

svenska (SV) (408.75 KB - PDF)

**First published:**

29/09/2025

**Last updated:**

31/10/2025

[View](/sv/documents/product-information/zurzuvae-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000304502 30/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zurzuvae : EPAR - All Authorised presentations

English (EN) (45.05 KB - PDF)

**First published:** 29/09/2025

[View](/en/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-370)

български (BG) (49.58 KB - PDF)

**First published:**

29/09/2025

[View](/bg/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.61 KB - PDF)

**First published:**

29/09/2025

[View](/es/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.43 KB - PDF)

**First published:**

29/09/2025

[View](/cs/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.9 KB - PDF)

**First published:**

29/09/2025

[View](/da/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.21 KB - PDF)

**First published:**

29/09/2025

[View](/de/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.94 KB - PDF)

**First published:**

29/09/2025

[View](/et/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.3 KB - PDF)

**First published:**

29/09/2025

[View](/el/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_el.pdf)

français (FR) (43.34 KB - PDF)

**First published:**

29/09/2025

[View](/fr/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (97.18 KB - PDF)

**First published:**

29/09/2025

[View](/hr/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.04 KB - PDF)

**First published:**

29/09/2025

[View](/is/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.84 KB - PDF)

**First published:**

29/09/2025

[View](/it/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.8 KB - PDF)

**First published:**

29/09/2025

[View](/lv/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (48.51 KB - PDF)

**First published:**

29/09/2025

[View](/lt/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (50.35 KB - PDF)

**First published:**

29/09/2025

[View](/hu/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (47.49 KB - PDF)

**First published:**

29/09/2025

[View](/mt/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (42.38 KB - PDF)

**First published:**

29/09/2025

[View](/nl/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (41.7 KB - PDF)

**First published:**

29/09/2025

[View](/no/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.31 KB - PDF)

**First published:**

29/09/2025

[View](/pl/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_pl.pdf)

português (PT) (41.93 KB - PDF)

**First published:**

29/09/2025

[View](/pt/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.34 KB - PDF)

**First published:**

29/09/2025

[View](/ro/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (46.45 KB - PDF)

**First published:**

29/09/2025

[View](/sk/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.95 KB - PDF)

**First published:**

29/09/2025

[View](/sl/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (42.27 KB - PDF)

**First published:**

29/09/2025

[View](/fi/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.26 KB - PDF)

**First published:**

29/09/2025

[View](/sv/documents/all-authorised-presentations/zurzuvae-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zurzuvae Active substance zuranolone International non-proprietary name (INN) or common name zuranolone Therapeutic area (MeSH) Depression, Postpartum Anatomical therapeutic chemical (ATC) code N06A

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Zurzuvae is indicated for the treatment of postpartum depression (PPD) in adults following childbirth (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/006488

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Biogen Netherlands B.V.

Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands

Opinion adopted 24/07/2025 Opinion status Positive Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zurzuvae  : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.39 KB - PDF)

**First published:** 31/10/2025

[View](/en/documents/procedural-steps-after/zurzuvae-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zurzuvae : EPAR - Public assessment report

Reference Number: EMA/264858/2025

English (EN) (4.23 MB - PDF)

**First published:** 29/09/2025

[View](/en/documents/assessment-report/zurzuvae-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zurzuvae

Adopted

Reference Number: EMADOC-628903358-125643

English (EN) (130.31 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zurzuvae_en.pdf)

#### News on Zurzuvae

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025) 25/07/2025

**This page was last updated on** 31/10/2025

## Share this page

[Back to top](#main-content)